Ulrich Freudensprung
AuthID: R-00G-J2Y
1
TÃTULO: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
AUTORES: Joseph Gligorov; Jose Bines; Emilio Alba; Giorgio Mustacchi; Saverio Cinieri; Vineet Gupta; Jean Yves Pierga; Hakan Bozcuk; Rabab Gaafar; Sudeep Gupta; Guillermo Lopez Vivanco; Xiaojia J Wang; Romulo Costa; Kadri Altundag; Ewa Chmielowska; Sabine de Ducla; Ulrich Freudensprung; Paulo Cortes; Dinesh Doval;
PUBLICAÇÃO: 2015, FONTE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, NÚMERO: 9
AUTORES: Joseph Gligorov; Jose Bines; Emilio Alba; Giorgio Mustacchi; Saverio Cinieri; Vineet Gupta; Jean Yves Pierga; Hakan Bozcuk; Rabab Gaafar; Sudeep Gupta; Guillermo Lopez Vivanco; Xiaojia J Wang; Romulo Costa; Kadri Altundag; Ewa Chmielowska; Sabine de Ducla; Ulrich Freudensprung; Paulo Cortes; Dinesh Doval;
PUBLICAÇÃO: 2015, FONTE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, NÚMERO: 9
INDEXADO EM: 
WOS 
CrossRef
WOS CrossRef2
TÃTULO: Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial Full Text
AUTORES: Joseph Gligorov; Dinesh Doval; Jose Bines; Emilio Alba; Paulo Cortes; Jean Yves Pierga; Vineet Gupta; Romulo Costa; Stefanie Srock; Sabine de Ducla; Ulrich Freudensprung; Giorgio Mustacchi;
PUBLICAÇÃO: 2014, FONTE: LANCET ONCOLOGY, VOLUME: 15, NÚMERO: 12
AUTORES: Joseph Gligorov; Dinesh Doval; Jose Bines; Emilio Alba; Paulo Cortes; Jean Yves Pierga; Vineet Gupta; Romulo Costa; Stefanie Srock; Sabine de Ducla; Ulrich Freudensprung; Giorgio Mustacchi;
PUBLICAÇÃO: 2014, FONTE: LANCET ONCOLOGY, VOLUME: 15, NÚMERO: 12
